In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
As a result, IZERVAY is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing GA. Astellas stands on the forefront of ...
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
"We are pleased with the FDA's decision to extend the use of IZERVAY for longer-term administration—further solidifying IZERVAY's status as a trusted choice for thousands of GA patients since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback